ABSTRACT
Introduction to assess the lipid-lowering effect, the effect on endothelial function, oxidative stress of Rosuvastatin at a dose of 40 mg in patients with dyslipidemia, arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) initially, over time after 4 weeks and 12 months of treatment.
Material and methods The prospective study included 33 patients (mean age 60 [54;61] years) with hypertension, COPD and dyslipidemia. The laboratory examination consisted of determining the lipid spectrum and the level of lipid peroxidation products (LPO). To assess the tolerability of the prescribed therapy, creatinine, bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were studied. To assess endothelial function, an endothelium-dependent vasodilation test (EDVD) was performed. Rosuvastatin at a dose of 40 mg was prescribed as lipid-lowering therapy. Initially, after 12 months, an ultrasound duplex scanning of the carotid arteries was performed to assess the presence of atherosclerotic plaques (AP) in the lumen of the vessel. The study was approved by the Local Ethics Committee of the Andes University in Merida, Venezuela (protocol No. 10 of December 25, 2017).
Results after 4 weeks of treatment with Rosuvastatin at a dose of 40 mg, there was a significant decrease in total cholesterol levels by 26%, low-density lipoproteins (LDL) by 33%, triglycerides (TG) by 19%, while high-density lipoproteins (HDL) increased by 18%. Improvements in endothelial dysfunction (ED) and lipid peroxidation were observed during treatment with Rosuvastatin. Treatment with Rosuvastatin at a dose of 40 mg did not cause adverse reactions in patients.
Conclusion correction of lipid metabolism disorders in patients with hypertension and COPD by prescribing Rosuvastatin at a dose of 40 mg can quickly reduce total cholesterol, LDL and TG, positively affecting endothelial function and lipid peroxidation processes. Therapy with Rosuvastatin at a starting dose of 40 mg in patients with dyslipidemia, hypertension and COPD is safe. After 12 months of regular use of Rosuvastatin at a dose of 40 mg, regression of AB was observed.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
0275
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Universidad de los Andes in Merida, Venezuela of protocol 0275 of the year 2017 gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
